Needham Have Target Price $55 on Surmodics (NASDAQ:SRDX). Researchers Reconfirmed firms Buy rating.

May 17, 2018 - By Stacey Dunning

Surmodics, Inc. (NASDAQ:SRDX) Corporate Logo

During Q4 2017 the big money sentiment decreased to 0.69. That’s change of 0.25, from 2017Q3’s 0.94. 11 investors sold all, 44 reduced holdings as Surmodics, Inc. ratio turned negative. 26 increased holdings while 12 funds acquired holdings. Funds hold 11.07 million shares thus 0.98% less from 2017Q3’s 11.18 million shares.

Limited Liability Corporation stated it has 0.01% of its capital in Surmodics, Inc. (NASDAQ:SRDX). Pnc Svcs Inc invested in 0% or 167 shs. Ny State Teachers Retirement Sys owns 43,262 shs. Gabelli Funds Ltd Llc reported 0.02% of its capital in Surmodics, Inc. (NASDAQ:SRDX). 8,400 are owned by Spark Ltd Com. Legal And General Pcl invested in 23,854 shs. 31,168 were accumulated by Rhumbline Advisers. Parallax Volatility Advisers Ltd Partnership reported 2,016 shs stake. Great West Life Assurance Can reported 18,374 shs. National Bank Of Ny Mellon Corporation invested in 155,922 shs. Ameriprise Fincl invested 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX). California State Teachers Retirement System invested 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX). Strs Ohio owns 23,800 shs. 49,119 were accumulated by Deutsche National Bank & Trust Ag. Barclays Public Ltd Company has invested 0% in Surmodics, Inc. (NASDAQ:SRDX).

Surmodics, Inc. registered $63,711 net activity with 0 insider buys and 2 insider sales since December 11, 2017.

Reiterated Surmodics (NASDAQ:SRDX) Rating.

Surmodics (NASDAQ:SRDX) had $55 PT given by Needham in a report revealed on 16 May. Research professionals’s target gives a potential upside of 11.79 % from the company’s previous close.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

In total 2 analysts cover Surmodics (NASDAQ:SRDX). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $5500 highest and $42 lowest target price Surmodics has $55 average target price or 11.79% above the current ($49.2) price. 4 are the (NASDAQ:SRDX)’s analyst reports since February 28, 2018 according to StockzIntelligence Inc. On Wednesday, May 16 the rating was maintained by Needham with “Buy”. On Wednesday, February 28 Barrington Research upgraded Surmodics, Inc. (NASDAQ:SRDX) to “Outperform” rating. On Wednesday, May 2 the rating was maintained by Needham with “Buy”.

Ticker’s shares touched $49.2 during the last trading session after 5.24% change.Surmodics, Inc. has 114,997 shares volume, 113.73% up from normal. SRDX is uptrending and has moved 61.37% since May 17, 2017. The stock outperformed the S&P 500 by 49.82%.

On August, 2 is anticipated Surmodics, Inc. (NASDAQ:SRDX)’s earnings report, Faxor reports. EPS of $-0.08 is 188.89 % down from 2017’s $0.09 EPS. Wall Street forecasts -214.29 % negative EPS growth as of August, 2.

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland.The firm is worth $652.29 million. It operates through two divisions, Medical Device and In Vitro Diagnostics.The P/E ratio is 24600. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

For more Surmodics, Inc. (NASDAQ:SRDX) news announced briefly go to: Seekingalpha.com, Globenewswire.com, Businesswire.com, Benzinga.com or Benzinga.com. The titles are as follows: “Surmodics’ (SRDX) CEO Gary Maharaj on Q2 2018 Results – Earnings Call Transcript” announced on May 02, 2018, “Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA …” on May 01, 2018, “Surmodics Announces Leadership Change and Appointment of Interim CFO” with a publish date: May 16, 2018, “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” and the last “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” with publication date: May 09, 2018.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: